Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Swiss sell-off

This article was originally published in The Gray Sheet

Executive Summary

Jomed could declare bankruptcy by April 2, when creditors will vote whether to make the company's preliminary suspension of debt payments final, as advised by Jomed administrators, the firm tells investors March 13. Meanwhile, the company is "intensifying the efforts of divesting certain assets," following completion of a deal with Edwards Lifesciences, involving Jomed's catheter-based heart valve repair technology (1"The Gray Sheet" Feb. 24, 2003, p. 15). By end of trading March 13, Jomed shares dropped $0.84, or 30%, to $2.02...

You may also be interested in...

Jomed Valve Repair Sale To Edwards Could Presage Additional Divestitures

Edwards Lifesciences will combine Jomed's catheter-based mitral heart valve repair technology with its own percutaneous R&D program under a two-pronged strategy to address a potential $800 mil. global market for the procedure

US FDA Still Seeking Sponsor Cooperation For Oncology Label Updates

Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.

Oncology Drug Safety Is Key Focus In US FDA’s Generic Label Updates

US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts